Your browser doesn't support javascript.
loading
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
Le Moigne, Ronan; Aftab, Blake T; Djakovic, Stevan; Dhimolea, Eugen; Valle, Eduardo; Murnane, Megan; King, Emily M; Soriano, Ferdie; Menon, Mary-Kamala; Wu, Zhi Yong; Wong, Stephen T; Lee, Grace J; Yao, Bing; Wiita, Arun P; Lam, Christine; Rice, Julie; Wang, Jinhai; Chesi, Marta; Bergsagel, P Leif; Kraus, Marianne; Driessen, Christoph; Kiss von Soly, Szerenke; Yakes, F Michael; Wustrow, David; Shawver, Laura; Zhou, Han-Jie; Martin, Thomas G; Wolf, Jeffrey L; Mitsiades, Constantine S; Anderson, Daniel J; Rolfe, Mark.
Afiliação
  • Le Moigne R; Cleave Biosciences, Inc., Burlingame, California. ronan.lemoigne29@gmail.com.
  • Aftab BT; Department of Medicine, Division of Hematology & Oncology, University of California San Francisco, San Francisco, California.
  • Djakovic S; Cleave Biosciences, Inc., Burlingame, California.
  • Dhimolea E; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Valle E; Cleave Biosciences, Inc., Burlingame, California.
  • Murnane M; Department of Medicine, Division of Hematology & Oncology, University of California San Francisco, San Francisco, California.
  • King EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Soriano F; Cleave Biosciences, Inc., Burlingame, California.
  • Menon MK; Cleave Biosciences, Inc., Burlingame, California.
  • Wu ZY; Cleave Biosciences, Inc., Burlingame, California.
  • Wong ST; Cleave Biosciences, Inc., Burlingame, California.
  • Lee GJ; Cleave Biosciences, Inc., Burlingame, California.
  • Yao B; Cleave Biosciences, Inc., Burlingame, California.
  • Wiita AP; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Lam C; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Rice J; Cleave Biosciences, Inc., Burlingame, California.
  • Wang J; Cleave Biosciences, Inc., Burlingame, California.
  • Chesi M; Comprehensive Cancer Center, Mayo Clinic, Scottsdale, Arizona.
  • Bergsagel PL; Comprehensive Cancer Center, Mayo Clinic, Scottsdale, Arizona.
  • Kraus M; Experimental Oncology and Hematology, Department of Oncology and Hematology, St. Gallen, Switzerland.
  • Driessen C; Experimental Oncology and Hematology, Department of Oncology and Hematology, St. Gallen, Switzerland.
  • Kiss von Soly S; Cleave Biosciences, Inc., Burlingame, California.
  • Yakes FM; Cleave Biosciences, Inc., Burlingame, California.
  • Wustrow D; Cleave Biosciences, Inc., Burlingame, California.
  • Shawver L; Cleave Biosciences, Inc., Burlingame, California.
  • Zhou HJ; Cleave Biosciences, Inc., Burlingame, California.
  • Martin TG; Department of Medicine, Division of Hematology & Oncology, University of California San Francisco, San Francisco, California.
  • Wolf JL; Department of Medicine, Division of Hematology & Oncology, University of California San Francisco, San Francisco, California.
  • Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Anderson DJ; Cleave Biosciences, Inc., Burlingame, California.
  • Rolfe M; Cleave Biosciences, Inc., Burlingame, California.
Mol Cancer Ther ; 16(11): 2375-2386, 2017 11.
Article em En | MEDLINE | ID: mdl-28878026
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Proteínas Nucleares / Adenosina Trifosfatases / Fator 1 Nuclear Respiratório / Inibidores de Proteassoma / Indóis / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Proteínas Nucleares / Adenosina Trifosfatases / Fator 1 Nuclear Respiratório / Inibidores de Proteassoma / Indóis / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2017 Tipo de documento: Article